Free Trial

Enfusion, Inc. (NYSE:ENFN) Insider Bronwen Bastone Sells 3,126 Shares

Enfusion logo with Computer and Technology background
Remove Ads

Enfusion, Inc. (NYSE:ENFN - Get Free Report) insider Bronwen Bastone sold 3,126 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the completion of the transaction, the insider now directly owns 221,875 shares in the company, valued at $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bronwen Bastone also recently made the following trade(s):

  • On Monday, March 3rd, Bronwen Bastone sold 2,064 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total value of $23,694.72.
  • On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $8,195.17.

Enfusion Stock Performance

ENFN stock traded up $0.04 during mid-day trading on Tuesday, reaching $11.15. The company had a trading volume of 780,007 shares, compared to its average volume of 1,156,687. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 278.69, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a fifty day simple moving average of $10.99 and a 200 day simple moving average of $9.92.

Remove Ads

Enfusion (NYSE:ENFN - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Institutional Trading of Enfusion

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Centiva Capital LP raised its position in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company's stock worth $243,000 after acquiring an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Enfusion by 4.8% in the 4th quarter. Mackenzie Financial Corp now owns 31,271 shares of the company's stock valued at $322,000 after buying an additional 1,434 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enfusion by 5.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company's stock valued at $289,000 after buying an additional 1,567 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Enfusion by 3.0% during the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company's stock worth $643,000 after acquiring an additional 1,796 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Stifel Nicolaus increased their price target on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler increased their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $11.13.

View Our Latest Stock Analysis on Enfusion

About Enfusion

(Get Free Report)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

Featured Stories

Insider Buying and Selling by Quarter for Enfusion (NYSE:ENFN)

Should You Invest $1,000 in Enfusion Right Now?

Before you consider Enfusion, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.

While Enfusion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads